Feeds:
Posts
Comments

Archive for 2014


The 100 Best Universities in the World Today

Reporter: Aviva Lev-Ari, PhD, RN

 

SOURCE

http://www.thebestschools.org/features/100-best-universities-in-world-today/

The 100 Best Universities in the World

Harvard University

1. Harvard University … [1st in U.S.],

(Cambridge, MA, USA)

 

 

 

2. Stanford University … [2nd in U.S.]

(Stanford, CA, USA)

 

Stanford University

 

 

 

 

3. Massachusetts Institute of Technology (MIT) … [3rd in U.S.]

MIT(Cambridge, MA, USA)

4. University of California at Berkeley … [4th in U.S.]

University of California Berkeley(Berkeley, CA, USA)

5. University of Cambridge

University of Cambridge

 

 

(Cambridge, UK)

 

 

 

Read Full Post »


Pace of Groundbreaking Research @The Weizmann Institute of Science

 

Reporter: Aviva Lev-Ari, PhD, RN

Discovering solutions to humanity’s most pressing issues

The Weizmann Institute of Science needs your help to ensure that the pace of groundbreaking research never falters. As one of the foremost centers of multidisciplinary research in the world, the Institute addresses the most urgent challenges facing humanity:

Cancer research: Developing a non-invasive, FDA-approved method to test for breast cancer without a biopsy
Technology: Inventing a DNA-based biological computer so tiny that a trillion can fit in a single drop of water
Education: Giving children the mentorship and guidance they need to pursue higher education in science and technology
Alternative Energy: Investigating algae as a source of clean, sustainable fuel
Health & Medicine: Creating vaccines for diabetes and flu; using stem cells to grow new organs; and examining conditions from Alzheimer’s to autism
Protecting Our Planet: Developing nanomaterials that serve as engine lubricants, thus reducing fuel consumption and air pollution

Weizmann scientists work in partnership with colleagues across the globe, their shared curiosity helping to create a better tomorrow.

SOURCE

http://weizmann-usa.org/support/donate/science-from-israel.html

Read Full Post »


GUIDE-seq: First genome-wide method of detecting off-target DNA breaks induced by CRISPR-Cas nucleases

Reporter: Aviva Lev-Ari, PhD, RN

 

Other related articles published in this Open Access Online Scientific Journal include the following:

CRISPR-Cas9 Foundational Technology – The definition of “Prior Art” is at a very high stack, June 2014.
For articles on CRISPR-Cas9 in Open Access Online Scientific Journal http://pharmaceuticalintelligence.com

click on

https://pharmaceuticalintelligence.com/?s=CRISPR-Cas9

On 6/16/2014 Dr. Aviva Lev-Ari published the following two articles:

Lecture Contents delivered at Koch Institute for Integrative Cancer Research, Summer Symposium 2014: RNA Biology, Cancer and Therapeutic Implications, June 13, 2014 @MIT
https://pharmaceuticalintelligence.com/2014/06/16/lecture-contents-delivered-at-koch-institute-for-integrative-cancer-research-summer-symposium-2014-rna-biology-cancer-and-therapeutic-implications-june-13-2014-mit/

Prediction of the Winner RNA Technology, the FRONTIER of SCIENCE on RNA Biology, Cancer and Therapeutics & The Start Up Landscape in Boston
https://pharmaceuticalintelligence.com/2014/06/16/prediction-of-the-winner-rna-technology-the-frontier-of-science-on-rna-biology-cancer-and-therapeutics-the-start-up-landscape-in-boston/

Other related articles on CRISPR-Cas9 Technology published on this Open Access Online Scientific Journal include the following:
2:15 – 2:45, 6/13/2014, Jennifer Doudna “The biology of CRISPRs: from genome defense to genetic engineering”

https://pharmaceuticalintelligence.com/2014/06/13/215-245-6132014-jennifer-doudna-the-biology-of-crisprs-from-genome-defense-to-genetic-engineering/https://pharmaceuticalintelligence.com/2014/06/13/215-245-6132014-jennifer-doudna-the-biology-of-crisprs-from-genome-defense-to-genetic-engineering/

Ribozymes and RNA Machines – Work of Jennifer A. Doudna

https://pharmaceuticalintelligence.com/2013/04/15/ribozymes-and-rna-machines-work-of-jennifer-a-doudna/
CRISPR @MIT – Genome Surgery

https://pharmaceuticalintelligence.com/2014/04/21/crispr-mit-genome-surgery/

Gene Therapy and the Genetic Study of Disease: @Berkeley and @UCSF – New DNA-editing technology spawns bold UC initiative as Crispr Goes Global

https://pharmaceuticalintelligence.com/2014/03/27/gene-therapy-and-the-genetic-study-of-disease-berkeley-and-ucsf-new-dna-editing-technology-spawns-bold-uc-initiative-as-crispr-goes-global/

Diagnosing Diseases & Gene Therapy: Precision Genome Editing and Cost-effective microRNA Profiling

https://pharmaceuticalintelligence.com/2013/03/28/diagnosing-diseases-gene-therapy-precision-genome-editing-and-cost-effective-microrna-profiling/

An expanded-DNA Biology from Scripps Research Institute: Beyond A-T and C-G: Applications for new Medicines and Nanotechnology

https://pharmaceuticalintelligence.com/2014/05/11/an-expanded-dna-biology-from-scripps-research-institute-beyond-a-t-and-c-g-applications-for-new-medicines-and-nanotechnology/

Evaluate your Cas9 Gene Editing Vectors: CRISPR/Cas Mediated Genome Engineering – Is your CRISPR gRNA optimized for your cell lines?

https://pharmaceuticalintelligence.com/2014/03/25/evaluate-your-cas9-gene-editing-vectors-crisprcas-mediated-genome-engineering-is-your-crispr-grna-optimized-for-your-cell-lines/

 

 

 

GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

Nature Biotechnology (2014) doi:10.1038/nbt.3117

Abstract

CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint ‘hotspots’. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use.

SOURCE

Gene-Editing Guide

Wed, 12/17/2014 – 4:42pm
Sue McGreevy, Harvard University
CRISPR-Cas9 gene-editing complex from Streptococcus pyogenes. Image: iStock
CRISPR-Cas9 gene-editing complex from Streptococcus pyogenes. Image: iStock

 

Read Full Post »


CONTROLLED RELEASE FORMULATION OF ANTIHYPERTENSIVE DRUGS: Design and Optimization of Controlled Release Formulations for Calcium Channel Blockers Offer Price $114.00 ISBN:3844392416 Authors Dr. Dheeraj Baviskar, Dr.

Source: booksonthemove.com

See on Scoop.itCardiotoxicity

Read Full Post »


People have been altering consciousness for a long time.

Source: www.businessinsider.com

See on Scoop.itCardiotoxicity

Read Full Post »


Beta-blockers have been the standard treatment for people with Marfan’s syndrome, a rare inherited connective tissue disorder that affects about 1 in 5000 people.

Source: www.forbes.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »


https://www.youtube.com/v/4f0N0-Ctuy8?fs=1&hl=fr_FR

http://articles.mercola.com/sites/articles/archive/2014/01/29/beta-blockers-death.aspx Natural health expert and Mercola.com founder Dr. Joseph Mercola inter…

Source: www.youtube.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »


RT @CEOlNG: Dread meetings and presentations? Try beta blockers:
http://t.co/VRJrrpJ6lJ http://t.co/l7546Ehv4P

Source: www.eliteenvy.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »


Cardiology | CHICAGO — Beta-blocker use at discharge in patients with stable angina without prior history of MI or systolic HF undergoing elective PCI did not affect mortality at 30 days or 3 years, according to findings presented at the American …

Source: www.healio.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »


These are so much more important than doctors wearing Google Glass.

Source: www.businessinsider.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

« Newer Posts - Older Posts »